2025-11-05
12 分钟The government shutdown nears a record as the longest in U.S.
history.
Plus,
what an ominous milestone for a famous method of valuing stocks tells us about what's next for markets.
It's proven to be an extremely reliable indicator of what to expect in the several years ahead of us.
And former Vice President Dick Cheney, an architect of the U.S.
War on Terror, has died at 84.
It's Tuesday, November 4th.
I'm Sabrina Sidiki for The Wall Street Journal, sitting in for Alex Osala.
This is the PM edition of What's News,
the top headlines and business stories that move the world today.
The Trump administration is negotiating with Eli Lilly and Novo Nordisk to offer their blockbuster weight loss drugs at lower prices as low as $149 for a month's supply through a Trump-branded government website
for buying medications.
People familiar with the matter say the proposed agreements would also mean Medicare and Medicaid coverage of expensive obesity drugs like Wigowi and Zepbound.
Medicare drug benefit plans today can cover the weight loss drugs just not only for losing weight.
For example, they're available for reducing risk of heart attacks or sleep apnea.
And few states offer Medicaid coverage for the drugs for weight loss.
And that's not the only news today about the weight loss drug market.
There's a new twist in the high stakes bidding war for the obesity drug developer Metzera as Novo Nordisk and Pfizer have both raised their offers for the company.
Metzera said today that Novo Nordisk's proposal values the company at approximately $10 billion,